Nonetheless, this information, along with the continual generation of promising clinical and pre-clinical results seen with epigenetic drugs against chromatin regulators such as LSD1 may signify the central role of epigenetics in breast cancer. This evidence concerns the gene KDM1A and breast carcinoma.